Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

  • Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1
     
  • Subgroup analyses of the EXPAND trial showed the value of early treatment initiation with Mayzent in patients with active SPMS as positive effects on disability, cognitive processing speed and relapse outcomes were sustained for up to five years2
     
  • Results from EXCHANGE interim analysis presented at ACTRIMS-ECTRIMS reinforced its safety and tolerability …
/by

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

  • New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide1
  • Additional safety data in over 1,800 patients who continued Kesimpta treatment or switched therapy from previous studies reinforce the favorable safety profile of Kesimpta in patients with relapsing forms of multiple sclerosis (RMS)2
     
  • Baseline serum …
/by

Not your grandparents’ nuclear medicine

In the late 1800s, at a time when people still traveled in horse-drawn carriages and lit homes with wax candles, scientists discovered nuclear power. They found curious elements, such as uranium and radium, which emit invisible rays of energy. They called this energy radiation. 

When they noticed that radiation had the power to burn skin, they applied it to treat cancer. The benefits were evident, but it would take scientists decades to understand how to wield the energy that emerges from the core of these special atoms safely.

Now, a new form of nuclear medicine is on the …

/by